SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company

Core Insights - SciSparc Ltd. announced that its majority-owned subsidiary NeuroThera Labs Inc. will acquire a 55% equity interest in a pioneering quantum computing bio data company, with the transaction involving the issuance of common shares equivalent to 40% of NeuroThera's share capital [1][3] Group 1: Acquisition Details - The acquisition is based on a non-binding term sheet and is subject to due diligence, negotiation of definitive agreements, and regulatory approvals [1][3] - The Target Company specializes in quantum-enabled clinical analytics, which aims to enhance the efficiency of bio data storage, manipulation, and analysis [2] Group 2: Quantum Computing Impact - Quantum computing principles such as superposition and entanglement are expected to revolutionize clinical trials by integrating quantum intelligence with bioinformatics [2] - This innovative approach aims to unlock precision and speed in medical research and development, potentially leading to superior machine learning performance [2] Group 3: Company Background - SciSparc Ltd. focuses on developing cannabinoid pharmaceuticals through its subsidiary NeuroThera, which is engaged in drug development programs targeting conditions like Tourette syndrome and Alzheimer's disease [4] - NeuroThera Labs Inc. is dedicated to creating novel therapeutics for central nervous system disorders and other underserved health conditions [5]